Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366664 · ClinicalTrials.gov registry record · Phase 1
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01366664 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 24 participants.
The verdict
NCT01366664, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacodynamics (the actions or effects a drug has on the body), pharmacokinetics (blood levels), safety, and tolerability of dapoxetine 60 mg when concomitantly administered in participants taking terazosin.
Interventions
- DRUG Treatment sequence 2
- DRUG Treatment sequence 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01366664
The ClinicalTrials.gov registry entry for NCT01366664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment sequence 2 is the first listed.
NCT01366664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01366664 about?
NCT01366664 is a clinical study titled "A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin". The purpose of this study is to assess the pharmacodynamics (the actions or effects a drug has on the body), pharmacokinetics (blood levels), safety, and tolerability of dapoxetine 60 mg when concomitantly administered in participants taking terazosin.
What is the current status of trial NCT01366664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01366664?
The interventions under investigation include: Treatment sequence 2 (DRUG), Treatment sequence 1 (DRUG).
Who is sponsoring clinical trial NCT01366664?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.